196 related articles for article (PubMed ID: 16956903)
1. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.
Wacke R; Förster S; Adam U; Mundkowski RG; Klar E; Hopt UT; Drewelow B
J Antimicrob Chemother; 2006 Nov; 58(5):994-9. PubMed ID: 16956903
[TBL] [Abstract][Full Text] [Related]
2. Vitreal penetration of oral moxifloxacin in humans.
Lott MN; Fuller JJ; Hancock HA; Singh J; Singh H; McGwin G; Marcus DM
Retina; 2008 Mar; 28(3):473-6. PubMed ID: 18327141
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin penetration into human gastrointestinal tissues.
Wirtz M; Kleeff J; Swoboda S; Halaceli I; Geiss HK; Hoppe-Tichy T; Büchler MW; Friess H
J Antimicrob Chemother; 2004 May; 53(5):875-7. PubMed ID: 15056642
[TBL] [Abstract][Full Text] [Related]
4. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty.
Malincarne L; Ghebregzabher M; Moretti MV; Egidi AM; Canovari B; Tavolieri G; Francisci D; Cerulli G; Baldelli F
J Antimicrob Chemother; 2006 May; 57(5):950-4. PubMed ID: 16551691
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis.
Stass H; Rink AD; Delesen H; Kubitza D; Vestweber KH
J Antimicrob Chemother; 2006 Sep; 58(3):693-6. PubMed ID: 16895940
[TBL] [Abstract][Full Text] [Related]
6. Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery.
Metallidis S; Charokopos N; Nikolaidis J; Alexiadou E; Lazaraki G; Koumentaki E; Tsona A; Theodoridis G; Nikolaidis P
Int J Antimicrob Agents; 2006 Nov; 28(5):428-32. PubMed ID: 17034992
[TBL] [Abstract][Full Text] [Related]
7. Penetration of moxifloxacin into liver tissue.
Justinger C; Schilling MK; Kees MG; Kauffels A; Hirschmann K; Kopp B; Kees F; Kollmar O
Int J Antimicrob Agents; 2012 Jun; 39(6):505-9. PubMed ID: 22526014
[TBL] [Abstract][Full Text] [Related]
8. Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections.
Ober MC; Hoppe-Tichy T; Köninger J; Schunter O; Sonntag HG; Weigand MA; Encke J; Gutt C; Swoboda S
J Antimicrob Chemother; 2009 Nov; 64(5):1091-5. PubMed ID: 19734170
[TBL] [Abstract][Full Text] [Related]
9. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Vedantham V; Lalitha P; Velpandian T; Ghose S; Mahalakshmi R; Ramasamy K
Eye (Lond); 2006 Nov; 20(11):1273-8. PubMed ID: 16200061
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration.
Goudah A; Hasabelnaby S
Res Vet Sci; 2010 Jun; 88(3):507-11. PubMed ID: 20004428
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration.
Fuhrmann V; Schenk P; Jaeger W; Ahmed S; Thalhammer F
J Antimicrob Chemother; 2004 Oct; 54(4):780-4. PubMed ID: 15347636
[TBL] [Abstract][Full Text] [Related]
12. Disposition kinetics of moxifloxacin in lactating ewes.
Goudah A
Vet J; 2008 Nov; 178(2):282-7. PubMed ID: 17900948
[TBL] [Abstract][Full Text] [Related]
13. Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients.
Esposito S; Noviello S; D'Errico G; Motta G; Passali D; Aimoni C; Pilucchi S; Fallani S; Cassetta MI; Mazzei T; Novelli A
J Antimicrob Chemother; 2006 Apr; 57(4):789-92. PubMed ID: 16504997
[TBL] [Abstract][Full Text] [Related]
14. Vitreal penetration of oral and topical moxifloxacin in humans.
Fuller JJ; Lott MN; Henson NM; Bhatti AA; Singh H; McGwin G; Marcus DM
Am J Ophthalmol; 2007 Feb; 143(2):338-40. PubMed ID: 17258525
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and milk penetration of moxifloxacin after intravenous and subcutaneous administration to lactating goats.
Fernández-Varón E; Villamayor L; Escudero E; Espuny A; Cárceles CM
Vet J; 2006 Sep; 172(2):302-7. PubMed ID: 15908243
[TBL] [Abstract][Full Text] [Related]
16. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment.
Barth J; Jäger D; Mundkowski R; Drewelow B; Welte T; Burkhardt O
J Antimicrob Chemother; 2008 Sep; 62(3):575-8. PubMed ID: 18515790
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients.
Kees MG; Weber S; Kees F; Horbach T
J Antimicrob Chemother; 2011 Oct; 66(10):2330-5. PubMed ID: 21729931
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
Florian JA; Tornøe CW; Brundage R; Parekh A; Garnett CE
J Clin Pharmacol; 2011 Aug; 51(8):1152-62. PubMed ID: 21228407
[TBL] [Abstract][Full Text] [Related]
19. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers.
Wagenlehner FM; Kees F; Weidner W; Wagenlehner C; Naber KG
Int J Antimicrob Agents; 2008 Jan; 31(1):21-6. PubMed ID: 18054465
[TBL] [Abstract][Full Text] [Related]
20. Aqueous humor and plasma concentrations of ciprofloxacin and moxifloxacin following topical ocular administration in ophthalmologically normal horses.
Clode AB; Davis JL; Salmon J; LaFevers H; Gilger BC
Am J Vet Res; 2010 May; 71(5):564-9. PubMed ID: 20433383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
